Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab Combined with Cadonilimab in ES-SCLC
NCT06620796Phase 2Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Sep 2024
- Primary completion
- Sep 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Phase 2, open-label trial of ivonescimab and cadonilimab in small cell lung cancer (SCLC) (2 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: 6-month Progression-Free Survival rate. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
ivonescimabcadonilimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06620796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06620796.